ZIM
ALLO icon

Zacks Investment Management’s Allogene Therapeutics ALLO Stock Holding History

Zacks Investment Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-192,731
Closed -$264K – 710
2025
Q4 		$264K Sell
192,731
-333,401
-63% -$440K ﹤0.01% 610
2025
Q3 		$652K Buy
526,132
+13,831
+3% +$16.5K 0.01% 452
2025
Q2 		$579K Sell
512,301
-6,540
-1% -$8.69K 0.01% 458
2025
Q1 		$758K Buy
518,841
+37,967
+8% +$71.6K 0.01% 430
2024
Q4 		$1.02M Sell
480,874
-35,727
-7% -$88.1K 0.01% 417
2024
Q3 		$1.45M Buy
+516,601
New +$1.38M 0.01% 376
2024
Q2 		– Sell
-459,800
Closed -$2.06M – 622
2024
Q1 		$2.06M Buy
459,800
+67,357
+17% +$281K 0.02% 307
2023
Q4 		$1.26M Buy
+392,443
New +$1.11M 0.02% 353

Other funds holding ALLO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Zacks Investment Management's ALLO Position: Q1 2026 in Review

Zacks Investment Management sold out of Allogene Therapeutics (ALLO) in Q1 2026, closing a stake of 192,731 shares — an estimated $264K sold.

Zacks Investment Management first reported a position in ALLO in Q4 2023 and held it in 8 quarters. The position peaked at $2.06M in Q1 2024. 209 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Zacks Investment Management reported no remaining Allogene Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Zacks Investment Management sold 192,731 Allogene Therapeutics shares in Q1 2026, an estimated $264K.
  • Zacks Investment Management first reported a position in Allogene Therapeutics in Q4 2023 and held it in 8 quarters.
  • Zacks Investment Management's Allogene Therapeutics position peaked at $2.06M in Q1 2024.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Zacks Investment Management's 13F filing for Q1 2026, filed 14 May 2026.